Literature DB >> 21444892

Biological basis of therapeutic lymphangiogenesis.

Camilla Norrmén1, Tuomas Tammela, Tatiana V Petrova, Kari Alitalo.   

Abstract

Mesh：

Year:  2011        PMID： 21444892     DOI： 10.1161/CIRCULATIONAHA.107.704098

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  51 in total

Review 1.  The new era of the lymphatic system: no longer secondary to the blood vascular system.

Authors:  Inho Choi; Sunju Lee; Young-Kwon Hong
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 2.  The lymphatic vasculature in disease.

Authors:  Kari Alitalo
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

3.  lyve1 expression reveals novel lymphatic vessels and new mechanisms for lymphatic vessel development in zebrafish.

Authors:  Kazuhide S Okuda; Jonathan W Astin; June P Misa; Maria V Flores; Kathryn E Crosier; Philip S Crosier
Journal:  Development       Date:  2012-05-23       Impact factor: 6.868

Review 4.  Receptor tyrosine kinase-mediated angiogenesis.

Authors:  Michael Jeltsch; Veli-Matti Leppänen; Pipsa Saharinen; Kari Alitalo
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-09-01       Impact factor: 10.005

5.  All vessels are not created equal.

Authors:  Diane R Bielenberg; Patricia A D'Amore
Journal:  Am J Pathol       Date:  2013-02-17       Impact factor: 4.307

6.  Update on the biology and treatment of lymphedema.

Authors:  Stanley G Rockson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-04

7.  A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.

Authors:  Elena Kurenova; Deniz Ucar; Jianqun Liao; Michael Yemma; Priyanka Gogate; Wiam Bshara; Ulas Sunar; Mukund Seshadri; Steven N Hochwald; William G Cance
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

8.  Imidazole-based alkaloid derivative LCB54-0009 suppresses ocular angiogenesis and lymphangiogenesis in models of experimental retinopathy and corneal neovascularization.

Authors:  Byung-Hak Kim; Junyeop Lee; Jun-Sub Choi; Dae Young Park; Ho Young Song; Tae Kyo Park; Chung-Hyun Cho; Sang-Kyu Ye; Choun-Ki Joo; Gou Young Koh; Tae-Yoon Kim
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

9.  Segregated Foxc2, NFATc1 and Connexin expression at normal developing venous valves, and Connexin-specific differences in the valve phenotypes of Cx37, Cx43, and Cx47 knockout mice.

Authors:  Stephanie J Munger; Xin Geng; R Sathish Srinivasan; Marlys H Witte; David L Paul; Alexander M Simon
Journal:  Dev Biol       Date:  2016-03-04       Impact factor: 3.582

10.  Lymphangiogenic therapy prevents cardiac dysfunction by ameliorating inflammation and hypertension.

Authors:  LouJin Song; Xian Chen; Terri A Swanson; Brianna LaViolette; Jincheng Pang; Teresa Cunio; Michael W Nagle; Shoh Asano; Katherine Hales; Arun Shipstone; Hanna Sobon; Sabra D Al-Harthy; Youngwook Ahn; Steven Kreuser; Andrew Robertson; Casey Ritenour; Frank Voigt; Magalie Boucher; Furong Sun; William C Sessa; Rachel J Roth Flach
Journal:  Elife       Date:  2020-11-17       Impact factor: 8.140
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.